Immune system response to Varicella-zoster virus antigens

Immune system response to Varicella-zoster virus antigens" describes a complex network of innate and adaptive immune mechanisms activated in response to infection by the Varicella-zoster virus (VZV). This process is not a single molecule or receptor, but rather involves multiple cell types (e.g., dendritic cells, T cells, B cells, macrophages, NK cells) and molecular sensors (e.g., Toll-like receptors [TLR2, TLR9], NLRP3 inflammasome, MDA5, RIG-I, STING) that detect VZV components and coordinate the secretion of cytokines (including type I interferons), activation of cellular immune responses, and production of neutralizing antibodies. Innate immunity (through interferons and NK cells) provides initial control and triggers adaptive immunity. Adaptive immune responses, especially VZV-specific T cells and antibodies, are crucial for viral clearance, controlling latency, and preventing reactivation (shingles)[1][4][5][6]. VZV has evolved several mechanisms to evade or modulate these immune responses, including interfering with pattern recognition, cytokine signaling, and apoptosis, making host immunity essential to both acute control and lifelong latency management[2][4]. Summary: This entity is a biological process, not a canonical drug or biologic target. If a specific molecular target is needed (such as a receptor, enzyme, or cytokine involved in VZV immunity), examples include "Toll-like receptor 2", "Toll-like receptor 9", or "NLRP3 inflammasome," each of which could be treated as a molecular target for structured annotation.

Other names

Immune response to Varicella-zoster virusVZV-specific immune responseVaricella-zoster virus immunological response

Stimulation of adaptive immunity (by vaccines) Inhibition of viral replication (by antivirals)